DGAP-News: Apricus Biosciences Announces Appointment of Dr. Kleanthis G. Xanthopoulos to Its Board o
(businesspress24) - Apricus Biosciences, Inc.
21.11.2011 15:51
---------------------------------------------------------------------------
SAN DIEGO, 2011-11-21 15:51 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
announced today that Kleanthis G. Xanthopoulos, Ph.D., President and Chief
Executive Officer of Regulus Therapeutics Inc. ('Regulus'), has been appointed
to the Company's Board of Directors, effective immediately.
Prior to joining Regulus in 2007, Dr. Xanthopoulos was the Managing Director of
Enterprise Partners Venture Capital. He co-founded Anadys Pharmaceuticals,
served as President and Chief Executive Officer from 2000 to 2006, and remained
a Director until its acquisition by Roche in 2011. Before that, Dr.
Xanthopoulos was Vice President at Aurora Biosciences (acquired by Vertex
Pharmaceuticals) from 1997 to 2000, and Section Head of the National Human
Genome Research Institute from 1995 to 1997.
Previously, he was an Associate Professor at the Karolinska Institute,
Stockholm, Sweden, after completing a Postdoctoral Research Fellowship at The
Rockefeller University, New York. An Onassis Foundation scholar, Dr.
Xanthopoulos received his B.Sc. in Biology with honors from Aristotle
University of Thessaloniki, Greece, and his M.Sc. in Microbiology and Ph.D. in
Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos is
a member of the board of directors of the Biotechnology Industry Organization
(BIO), Sente Inc., and a member of the executive board of BIOCOM, Southern
California's life science industry association.
Bassam Damaj, Ph.D., President and Chief Executive Officer of Apricus Bio,
stated, 'We are very happy to welcome Dr. Xanthopoulos to our Board of
Directors. His proven leadership as the CEO of Regulus and Anadys
Pharmaceuticals, plus his extensive business and corporate development
experience in the pharmaceutical industry, will be invaluable to us as we
continue to pursue our product commercialization strategy.'
Dr. Xanthopoulos added, 'I am very excited to join the board of this rapidly
growing specialty bio-pharmaceutical company. I look forward to working with
Dr. Damaj and his experienced business and scientific team to take Apricus Bio
and its portfolio of leading edge products based on its proprietary NexACT(r)
technology to the next level.'
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego-based, revenue-generating, biopharmaceutical company,
has leveraged the flexibility of its clinically-validated NexACT(r) drug delivery
technology to enable multi-route administration of new and existing compounds
across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the
development and commercialization of such compounds to pharmaceutical and
biotechnology companies worldwide. In addition, the Company is seeking to
monetize its existing Rx Division product pipeline, including its first
product, Vitaros(r), approved in Canada for the treatment of erectile
dysfunction, as well as compounds in development from pre-clinical through
Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology,
Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.
The Company is also developing its Consumer Healthcare Division by developing a
number of drugs that utilize the Company's NexACT(r) technology to comply with
the FDA's over-the-counter ('OTC') requirements, can be cleared as 510(k)
topical creams that are considered to be medical devices or approved as
505(b)(2) New Drug Applications ('NDAs') or Abbreviated New Drug Applications
('ANDAs') as generic drugs. The Company will also seek to market such drugs
through these similar procedures in foreign countries.
For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com . You
can also receive information at http://twitter.com/apricusbio and
http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further develop its products and
product candidates, to have its and their products and product candidates
approved by relevant regulatory authorities, to successfully commercialize such
products and product candidates and to achieve its and their other development,
commercialization and financial goals. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results could differ
materially from the forward-looking statements contained herein. Readers are
urged to read the risk factors set forth in the Company's most recent annual
report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from the SEC's
website or without charge from the Company.
CONTACT: Apricus Biosciences, Inc.
Edward Cox, V.P.
Investor Relations&Corporate Development
(858) 848-4249
ecox(at)apricusbio.com
Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz(at)rxir.com
News Source: NASDAQ OMX
21.11.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.11.2011 - 09:51 Uhr
Sprache: Deutsch
News-ID 524349
Anzahl Zeichen: 0
Kontakt-Informationen:
Ansprechpartner:
Stadt:
Telefon:
Kategorie:
Wirtschaft (allg.)
Anmerkungen:
Diese Pressemitteilung wurde bisher 197 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Apricus Biosciences Announces Appointment of Dr. Kleanthis G. Xanthopoulos to Its Board o"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
